Angiotech initiates Phase II trial with paclitaxel

Angiotech (ANPI; TSE:ANP) began a Phase II trial of its intravenous micellar paclitaxel to treat severe psoriasis in the U.S. Six patients who have failed at least 2 other systemic therapies for psori...